Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12096274 | 0.87 | KDM1A (0.46) | SMN1; SMN2ALDH1A1RAB9ANPC1MEN1 | |
| SCHEMBL2389958 | 0.84 | PDE4A (0.61) | SMN1; SMN2ALDH1A1RAB9ANPC1MEN1 | |
| SCHEMBL16911001 | 0.81 | MAPT (0.51) | SMN1; SMN2ALDH1A1RAB9ANPC1MEN1 | |
| SCHEMBL28052513 | 0.81 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1RAB9ANPC1MEN1 | |
| SCHEMBL30745584 | 0.80 | NOTUM (0.43) | ALDH1A1RAB9ANPC1KDM4ECYP17A1 | |
| SCHEMBL3103824 | 0.80 | NOTUM (0.43) | ALDH1A1RAB9ANPC1KDM4ECYP17A1 | |
| SCHEMBL8195799 | 0.80 | KMO (0.49) | SMN1; SMN2MEN1KMT2ALMNAHPGD | |
| SCHEMBL10200382 | 0.80 | PDE4A (0.45) | SMN1; SMN2ALDH1A1RAB9ANPC1MEN1 | |
| SCHEMBL16911720 | 0.80 | MAPT (0.54) | SMN1; SMN2ALDH1A1RAB9ANPC1MEN1 | |
| SCHEMBL6774958 | 0.78 | SCN4A (0.43) | ALDH1A1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200239427-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2020-07-30 | — | — | US | claimed |
| EP-3444242-A2 | NOVEL BENZOPYRAN KINASE MODULATORS | Rhizen Pharmaceuticals S.A. (CH) | 2019-02-20 | — | — | EP | claimed |
| EP-3050876-A2 | KINASE MODULATORS | Rhizen Pharmaceuticals S.A. (CH) | 2016-08-03 | — | — | EP | claimed |
| EP-2496567-A2 | NOVEL BENZOPYRAN KINASE MODULATORS | Rhizen Pharmaceuticals S.A. (CH) | 2012-09-12 | — | — | EP | claimed |
| WO-2011055215-A2 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-05-12 | — | — | WO | claimed |
| CN-112142745-B | Casein kinase 1 epsilon inhibitor, pharmaceutical composition and application thereof | 杭州和正医药有限公司 | 2023-03-21 | — | — | CN | disclosed |
| US-11524941-B2 | Pyrazole compounds as LSD1 inhibitors and applications thereof | MEDSHINE DISCOVERY INC. (CN) | 2022-12-13 | — | — | US | disclosed |
| CN-113968861-B | Compound with PI3K delta/BTK double-target-point activity and preparation method and application thereof | 杭州医学院 | 2022-10-21 | — | — | CN | disclosed |
| US-20220064126-A1 | Pyrazole Compounds As LSD1 Inhibitors And Applications Thereof | MEDSHINE DISCOVERY INC. (CN) | 2022-03-03 | — | — | US | disclosed |
| CN-113968861-A | Compound with PI3K delta/BTK double-target-point activity and preparation method and application thereof | 杭州医学院 | 2022-01-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064126-A1 | Pyrazole Compounds As LSD1 Inhibitors And Applications Thereof | KDM1B, KDM3A, KDM1A | SMN1; SMN2 2736/4885ALDH1A1 191/4885RAB9A 3109/4885 |
| US-11524941-B2 | Pyrazole compounds as LSD1 inhibitors and applications thereof | KDM1B, KDM3A, KDM1A | SMN1; SMN2 2736/4885ALDH1A1 191/4885RAB9A 3109/4885 |
| US-20200239427-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | SMN1; SMN2 2637/4885ALDH1A1 4305/4885RAB9A 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.